Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Justin Zhang

Critical Care · UCLA

View

Dr. Panagis Galiatsatos

Critical Care · Johns Hopkins

View

Dr. Kevin Chung

Critical Care · SeaStar Medical

View

Dr. Amos E. Dodi

Critical Care · MMC

View

Dr. Robert Hyzy

Critical Care · UMHS

View

Dr. Vin Gupta

Critical Care · Manatt Health

View

Dr. John Kellum

Critical Care · University of Pittsburgh

View

Dr. Christopher Worsham

Critical Care · Harvard Medical School

View

Dr. Kristin Walter

Critical Care · JAMA

View

Dr. Christopher Seymour

Critical Care · University of Pittsburgh

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study.

    Apr 30, 2026DOI: 10.1093/cid/ciaf252Journal ArticleCID

    Written by: Yewande E OdeyemiAysun TekinCaitlin C SchanzDiana J SchreierKristin ColeOgnjen GajicErin F Barreto

    Find these authors on Roon

    OG
    Dr. Ognjen Gajic
    Critical Care · Mayo Clinic College of Medicine

    Summary

    BACKGROUND: Doxycycline is a frequently used alternative treatment for community-acquired pneumonia (CAP) in hospitalized patients; however, the evidence base is limited. We aimed to compare outcomes in CAP patients treated with doxycycline or azithromycin in combination with beta-lactams.METHODS: We evaluated patients with CAP admitted to Mayo Clinic hospitals from May 2018 to September 2022 and treated with either azithromycin or doxycycline in combination with a beta-lactam. Patients who received both antibiotics or were on either antibiotic as chronic therapy prior to admission were excluded. The primary outcome was mortality. Patients were 1-to-1 matched according to the presence of congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, human immunodeficiency virus infection, recent immunosuppressant use, and pneumonia severity index class.RESULTS: Among 8492 patients (5810 for azithromycin, 2682 for doxycycline), 2671 doxycycline-treated patients were matched with azithromycin-treated patients. In-hospital mortality was significantly lower in the azithromycin group than in the doxycycline group (odds ratio, 0.71; 95% confidence interval [CI], .56-.9), as was 90-day mortality (hazard ratio, 0.83; 95% CI, .73-.95). Patients on azithromycin also had significantly more hospital-free days (HFDs) than those on doxycycline (estimate, 1.37; 95% CI, .99-1.74).CONCLUSIONS: Among hospitalized patients with CAP, azithromycin was associated with lower mortality and more HFDs compared with doxycycline in combination with beta-lactams. Randomized, controlled trials are needed to assess the effectiveness of each regimen and to compare their potential side effects.
    OGDr. Ognjen Gajic

    Dr. Ognjen Gajic

    Pulmonology & Critical Care · Critical Care Medicine
    Mayo Clinic
    ognjen